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Abstract Lithium is the most successful mood stabilizer
treatment for bipolar disorder. However, unlike conventional
drugs that are designed to interact with a specific molecular
target, the actions of lithium are distributed across many bio-
logical processes and pathways. Treatment response is subject
to genetic variation between individuals and similar genetic
variation may dictate susceptibility to side effects.
Transcriptomic, genomic, and cell-model research strategies
have all been deployed in the search for the genetic factors and
biological systems that mediate the interaction between genet-
ics and the therapeutic actions of lithium. In this review, recent
findings from genome-wide studies and patient cell lines will
be summarized and discussed from a standpoint that genuine
progress is being made to define clinically useful mechanisms
of this treatment, to place it in the context of bipolar disorder
pathology, and to move towards a time when the prescription
of lithium is targeted to those individuals who will derive the
greatest benefit.
Keywords Lithium . Bipolar disorder . Pharmacogenomics .
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Introduction to Lithium, the Mood Stabilizer
The serendipitous discoveries of therapeutic drugs are a fasci-
nating chapter in twentieth-century medicine. The application
of lithium as a treatment for mood disorders is one of the key
examples. In the late 1940s, John Cade, a psychiatrist working
inMelbourne, Australia accidentally discovered lithium’s sed-
ative properties during rodent experiments designed to ex-
plore the role of uric acid in psychiatric conditions (although
Cade knew about lithium as a historical treatment for uric acid
build up in gout) [1]. After a lengthy lag period caused by
concerns over its safety, the clinical development of lithium
for Bpsychotic excitement^, as Cade originally termed it, ac-
celerated in the 1960s and 1970s. Fifty years on, lithium is still
the Bgold standard^ treatment for bipolar disorder with cumu-
lative and overwhelming evidence for its therapeutic effective-
ness and consequent life-saving outcomes [2, 3].
In an era of rational high-throughput drug screening of
complex libraries chosen to represent the full dimensionality
of chemical space, it is somewhat bemusing to discover that
the blunt tool of a metal ion is a top-performing mood stabi-
lizer. This is a Bsmall molecule^ but without a single defined
Btarget^. Lithium ions possess a single positive charge and
have a radius of 76 pm [4]. We must assume that these 2
properties alone mediate its pharmacological action, most
likely bymimicking and compromising the actions and targets
of more physiologically relevant trace metals with similar
physical properties such as Cu+ (77 pm), Mg2+ (72 pm),
Zn2+ (74 pm), and the Bhigh spin^ form of Fe2+ (78 pm).
There is a stock view presented in numerous reviews of
therapeutic lithium that we understand little about the biolog-
ical mechanisms of its action. The sheer scale of lithium’s
potential physical interactions perhaps explains why it has
been so difficult to define its major biological modes of ac-
tion—both good and bad—until the advent of more sophisti-
cated and objective methodologies. A second confounding
factor has been the relative invisibility of lithium atoms in
X-ray crystallography. Consequently, any presumed function-
al interaction with a protein, such as glycogen synthase kinase
3β (GSK3β), has been very hard to confirm or characterize.
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The physical association of lithium and magnesium ions with
the phosphate chain of energy intermediate molecule, adeno-
sine triphosphate, has only recently been inferred by nuclear
magnetic resonance, and demonstrated to alter its purinergic
signaling capacity [5]. Likewise, lithium’s pharmacological
action within the catalytic site of (bacterial) inositol
monophosphatase has only been indirectly observed through
magnesium displacement upon increasing lithium concentra-
tions [6]. This review will acknowledge the technical chal-
lenges facing the field, but will also offer encouraging evi-
dence for progress from recent studies of the mechanisms of
lithium’s therapeutic action, the basis for its side effects, and
the genetic determinants of patient response.
Side Effects of Lithium
Given the lack of specificity, it is surprising that lithium’s thera-
peutic action is so potent and the toxic side effects not more
pronounced. It is, however, a close-run race—the therapeutic
index of lithium is very narrow, indicating dosages with thera-
peutic action are close to dosageswith toxic side effects. Patients
undergoinglithiumtreatmentrequireregularbloodtests toensure
that safe and effective levels are maintained. They also undergo
occasional assessment of kidney and parathyroid function: the 2
organs most susceptible to lithium toxicity. This potential for
harm provides a strongmotivation to deconvolute the biological
action of lithium to identify targets that could be pharmacologi-
callymanipulatedwithmore specific and less risky drugs and, in
addition, to define harmful Boff-target^ effects.
Multiple side effects of lithium have been described since it
was licensed for the treatment of acute mania and then bipolar
disorder in the 1970s. These include hypothyroidism, nausea,
diarrhea, and weight gain. However, it is the damage to the kid-
neys correlated with long-term use and excessive serum concen-
trations that is themostwell documentedandcharacterized [7–9].
Thisprimarilymanifestsasacommon(~50%ofpatients) increase
in thirst resulting from polyuria—excessive urination—and, less
commonly, as a progression to nephrogenic diabetes [10]. Both
states indicate a failure to concentrate urine in the collecting duct
ofthenephron.Theepithelialcellsofthecollectingductpermit the
entry of lithium through amiloride-sensitive ENaC sodium chan-
nels. As an aside, a recent paper described a screen for single-
nucleotide polymorphism (SNP) variants in selected candidate
genes that predispose those prescribed with lithium to long-term
deterioration of estimated glomerular filtration rates [11]. A CC
genotype at SNP rs378448, located in ACCN1, was identified as
the most significant predisposing factor. Additionally, a SNP in
the first exon of this gene has been associated with lithium re-
sponse in a small Sardinian cohort [12].ACCN1 encodes amem-
berof theENaCsuperfamily,but it isnotknownif thisplaysa role
inthecollectingductpathology.Oncelithiumenters theductcells,
there are many and, in some instances, hotly debated routes of
pathological action, including increased cyclooxygenase-2 ex-
pression generating prostaglandin E2, inhibition of GSK3β/
vasopressin action, decreased urea transporter expression, in-
creased cell-cycle activity leading to cellular remodeling, and re-
duced inositolmonophosphate/cyclic adenosinemonophosphate
signaling [13–15]. Ultimately, there is reduced induction and ex-
pression of the aquaporin-2 channels in the duct cell wall,
preventing the passive reuptake ofwater from the duct and there-
fore leading to the production of excess, dilute urine. Much less
common (~1%) in those prescribed lithium is a further chronic
progression to nephrotoxicity and histologically visible damage
to the kidney [16].
Adding to the complexity of the dosage balancing act is the
variable lithium response exhibited by each patient.
Approximately 30% of those prescribed lithium exhibit a
good response, with the remainder falling into partial- and
nonresponder groupings. This spectrum may be owing to het-
erogeneous genetic and environmental components—certain-
ly there is good evidence for heritable response to lithium in
bipolar disorder family clusters [17, 18]. Other factors that
correlate with response have been comprehensively reviewed
previously and include age–at–onset and periods of remission
[19]. Patient response might also directly relate to genetically
determined variation in lithium’s physiological availability,
excretion and molecular targets. For example, in the rat, the
major determinant of lithium reabsorption back into the blood-
stream from the kidney glomerular filtrate was recently iden-
tified as a foscarnet- and parathyroid hormone-sensitive sodi-
um–phosphate co-transporter activity. This raises the possibil-
ity that human genetic variation at this locus/loci could signif-
icantly influence the half-life of circulating lithium in the
bloodstream [20].
Archetypal Mediators of Lithium’s Therapeutic
Effects
In terms of lithium’s therapeutic action, there are a number of
classically studied proteins and pathways that are definitive
lithium targets. These have been reviewed extensively else-
where [21, 22]; only 2 will be briefly summarized here. First is
lithium’s known inhibition of the protein GSK3β [23–25].
This protein is a component of the WNT signaling pathway,
inhibition of which allows the accumulation of β-catenin pro-
tein and consequent downstream gene regulation. GSK3β al-
so regulates other proteins (e.g., arrestins) and is itself regu-
lated by other pathways (e.g., Akt). Second, an excess of ino-
sitol is believed to be a biochemical pathology in bipolar dis-
order affecting multiple cellular systems, including mitochon-
drial function, autophagy, growth cone function, and calcium
signaling. Lithium depletes this excess signaling by directly
inhibiting inositol monophosphatase 1—diverting the meta-
bolic pathway that generates inositol.
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Transcriptomic Approaches Struggle to Reveal
Lithium Action
In addition to these established modes of action, there are now
multidisciplinary approaches to fully characterize lithium’s
biology and the factors that influence a patient’s response.
One approach is to employ transcriptomic methods to identify
genes up- or downregulated in response to lithium treatment.
The premise is that these expression changes will reflect the
principal target genes and biological pathways that underlie
therapeutic action. However, the results have been disappoint-
ingly inconsistent. For this review, an informal analysis was
carried out on differentially expressed gene sets from 5 repre-
sentative transcriptomics papers spanning human/rodent stud-
ies and in vitro/vivo sample types [26–30]. This identified only
2 genes, CD93 and SULT1A1, shared between any 2 studies.
A more sophisticated analysis of this kind was carried out by
Breen et al. [31], to act as validation of their own gene expres-
sion study. The authors identified a number of results shared
across publications, including STC2, HADH, GAMT,MAT2A,
HSP90AA1, CRIP1, CKB, FOS, LAX1, and RSAD2, but, fur-
ther indicating the difficulties of the gene expression ap-
proach, these genes were not identified in the studies assessed
in this review. Many of these inconsistencies may lie in the
choice of cell type, treatment regimen, and even species.
Induced Pluripotent Stem Cells Offer a Means
to Explore Lithium Response in Well-Controlled
Human Models
The emergence of induced pluripotent stem (iPS) cell technolo-
gies has permitted the detailed investigation of mental illness in
biologically relevant human cell types. The acute nature of the
brain’s response to lithiumhas been convincinglymodeled in an
in vitro study of dentate gyrus-like neurons derived from 6 pa-
tients with bipolar disorder and 4 healthy control iPS cell lines
[32]. Disease-associated phenotype differences observed in the
patient neurons included altered mitochondrial function, abnor-
mal calciumsignaling, and,most noteworthy, a general hyperex-
citability manifested as increased sodium ion currents and in-
creased frequency of spontaneous action potentials. The authors
selected 3 good lithium responders and 3 nonresponders when
recruiting the cohortwith bipolar disorder. The hyperexcitability
phenotype was reversed by lithium treatment in the good re-
sponder subset alone: extraordinary evidence that the heteroge-
neous nature of complex genetic phenotypes can occasionally
Bcollapse^ into a simple and discriminatingmarker. The authors
went on to identified 45 genes with altered expression in bipolar
patient lines andbiological categorization of these confirmed the
involvement of mitochondrial processes. Importantly, the num-
ber of genes with significant expression changes in response to
lithium treatment was an order of magnitude greater in the
responding cells than in the nonresponding cells. Among these
genes were a number that have been previously implicated in
bipolar disorder (PDE11A,PRKCH,PTPRB, SCN11A,NKAIN,
KCNA1,andKCNJ12), indicating thatagoodresponse to lithium
correlates with a partial rescue of pathological gene expression
profiles. One of the disease-associated, lithium-responding
genes, KCNA1, was also identified in the study by McQuillin
et al. [26]. This gene encodes a potassium channel, proposed to
mediate a homeostatic response to the cellular hyperexcitability:
expression increases in disease, but decreases as lithium reverses
this electrophysiological phenotype. Similarly, the disease-asso-
ciated, lithium-responding genePde11a, encoding a phosphodi-
esterase that catabolizes cyclic adenosine monophosphate and
cyclic guanosine monophosphate, was shown to be expressed
at a lower levels in the hippocampi ofmouse strains that respond
to lithium[33].Pde11aknockoutmousestrainsalsodisplayedan
increased response to lithium compared with wild-type
littermates.
The iPS work above has been neatly complemented by a
recent publication that used lymphoblastoid cell-derived iPS
cells from patients with bipolar disorder and healthy control
cohorts of the same size and composition as above [34].When
differentiated into dentate gyrus-like granule cell neurons,
those from patients with bipolar disorder also displayed an
increased likelihood of the hyperexcitable phenotype.
However, a more discerning electrophysiological characteri-
zation of the cells revealed that lithium responder and nonre-
sponder lines achieved this hyperexcitability through different
perturbations in their underlying sodium and potassium chan-
nel activity and action potential parameters, with distinct elec-
trophysiological changes after lithium treatment. This enabled
the construction of a lithium response prediction model based
on electrophysiology alone.
A third study employing iPS cells generated from responsive
andnonresponsivepatients focusedon theproteomicchanges that
follow lithium treatment [35]. Of the 15 proteins identified with
altered expression or gel migration, collapsin response mediator
protein 2 (CRMP2)was chosen as an attractive candidate for fur-
ther study as it showed increased phosphorylation on threonine
position 514 in lithium-responsive patient iPS-derived neurons.
ThissitecanbephosphorylatedbyGSK3β(amongotherkinases),
and both lithium and a specific GSK3β inhibitor were shown to
reduce its phosphorylation level. CRMP2 regulates the cellular
response to semaphorin 3A (formerly known as Bcollapsin^), an
extracellular signaling molecule that binds to neuropilin/plexin
receptors. This pathway shapes dendritic spines and axonal
growth cone morphology during development and in the
adult—with implications for synapse formation and function.
Spinemorphologieswere shown to be altered in vitro and in post-
mortem brain samples, suggesting this is a genuine bipolar disor-
der pathology, and one that can be ameliorated by lithium, most
likely through action on the GSK3β/CRMP2/semaphorin 3A
pathway. The antidepressant tianeptine, antiepileptic lacosamide,
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and neurotrophic brain metabolite lanthionine ketimine have all
been shown to act on CRMP2 [36].
Together, these studies have created overlapping frame-
works of disease pathology and drug action that significantly
advance our understanding and provide discerning functional
assays for drug development and pharmacogenomic profiling.
The Era of Genome-Wide Studies Into Lithium
Response
Objective genome-wide approaches to study complex genetic
disorders, such as SNP-based association and high-throughput
sequencing, have also been instrumental in the search for nov-
el facets of pathology and pharmacogenomics across the full
range of complex genetic disorders. A key step in the assess-
ment of disease-predisposing genetic risk factors in associa-
tion studies is to compensate for false positives that will inev-
itably arise when genotyping hundreds of thousands of genetic
variants in each individual—patient or healthy control. Rather
than use the standard statistically significant p-value threshold
of 0.05, the requirement is for a p-value of 10–8 to be met, or
surpassed, before a finding can be considered Bgenome-wide
significant^. For bipolar disorder, the emergence of genome-
wide significant variants within calcium channel genes per-
haps offers the most pharmacologically tractable finding from
the multitude of genes discovered and validated [37, 38].
Direct assessment of lithium response factors via genome-
wide association study has been reported in 4 studies with
sufficient participants to be considered adequately powered
(see Table 1 for summary). The phenotypic definition of lith-
ium response at the level of the patient is most often achieved
using the ‘Alda’ rating scale based on case notes and
prescription history [17]. As with all psychiatric disorders,
there is no other clear physical biomarker that can be
employed for this purpose. Discounting the new evidence
for in vitro electrophysiological changes, there is only one
in vivo physical measure that could act as a quantifiable phe-
notype: the robust association of brain region size increases
that correlate with extended lithium use [39]. A correlation
with lithium response has not been tested (although perhaps
inferable from long-term use) but would be an indication that
cell proliferation/cell size are additional pathologies worthy of
exploration. The first of the 4 genome-wide studies failed to
reach statistical significance at any SNP locus [40]. However,
the second study, despite being made up of only 264 patients
with bipolar disorder, and then a further 100 patients in a
validation study, achieved extremely significant p-values for
SNP markers within GADL1 [41]. Depending on the parame-
ters used in the definition of lithium response, the p-values for
the most significant SNP, rs17026688, were between 9.19 ×
10−18 and 5.50 × 10−37. This extraordinary level of signifi-
cance, and associated effect size, should be practically predic-
tive for patient lithium response. The gene encodes the gluta-
mate decarboxylase-like protein 1 that, because of its se-
quence similarity to γ-aminobutryic acid-ergic metabolism
enzymes glutamate decarboxylase 1 and 2, appears a plausible
candidate. However, GADL1 is seemingly not expressed in
the brain and is principally engaged in taurine metabolism
[42]. While there is validation of this GWAS finding in a
second study in the Han Chinese population [43], other pop-
ulation studies have failed to replicate association [44, 45],
which suggests that the gene’s candidacy should be treated
with a level of caution until a statistical consensus emerges.
In the third study, a number of association comparisons were
made across several collected cohorts in which lithium
Table 1 Summary of the top findings from 3 genome-wide association studies of lithium response
SNP identifier Chromosome Implicated gene p-value Comment
Chen et al. [41]
rs17026688 3 GADL1 5.50 × 10−37 Discovery cohort
Hou et al. [49]
rs79663003 21 AL157359 1·37 × 10–8 European/Asian ancestry cohorts combined
rs78015114 21 AL157359 1·31 × 10–8 European/Asian ancestry cohorts combined
rs74795342 21 AL157359 3·31 × 10–9 European/Asian ancestry cohorts combined
rs75222709 21 AL157359 3·50 × 10–9 European/Asian ancestry cohorts combined
rs9662615 1 CSMD2 5·26 × 10–7 European cohort alone
rs771148 1 CSMD2 7·01 × 10–7 European cohort alone
rs61549860 7 HDAC9 5·44 × 10–7 European cohort alone
Song et al. [46, 47]
rs146727601 11 PTS,<space> PLET1 1.22 × 10−9 Corrigenda p-value
rs77866734 19 TCF3, KIR3DP1, KIR2DL4 7.59 × 10−7 Corrigenda p-value
p-Values in bold indicate genome-wide significant findings
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response was either subjectively (self-) reported or objectively
assessed [46, 47]. The only case–control permutation which
yielded genome-wide statistical significance was between 387
objectively assessed lithium responders and 6684 healthy con-
trols. This pinpointed a SNP, rs146727601 (p-value:1.22 ×
10−9), located within the gene, PTS , encoding 6-
pyruvoyltetrahydropterin synthase, an enzyme that partici-
pates in the synthesis of the cofactor tetrahydrobiopterin
(BH4). BH4 aids the production of nitric oxide and mono-
amine neurotransmitter synthesis. However, a mouse knock-
out of Pts alters metabolism and abdominal fat distribution
without an overt central nervous system phenotype or pertur-
bation of neurotransmitter levels [48]. There are other SNPs in
this study that fall marginally below the genome-wide statis-
tical threshold but which have intriguing links to established
psychiatric biology, suggesting that larger surveys are re-
quired. Finally, a fourth study carried out by the Consortium
on Lithium Genetics (ConLiGen) consisted of a genome-wide
association study of 2563 individuals diagnosed with bipolar
disorder and phenotypically assessed for lithium response
using both continuous and categorical assessment tools [49].
Marginally sub-genome-wide significant SNPs were identi-
fied using the continuous phenotypic model in the genes
CSMD2 [rs9662615 (p = 5·26×10–7); gene previously impli-
cated in multiple neuropsychiatric diagnoses [50]] and
HDAC9 [rs61549860 (p = 5·44×10–7); gene disrupted in one
reported case of schizophrenia [51]]. However, a cluster of
genome-wide significant SNPs was identified on chromosome
21 over a potential long noncoding mRNA associated with an
expressed sequence tag with accession number AL157359
(most significant SNP rs74795342; p = 3·31×10–9). The bio-
logical significance of this transcript is currently unknown.
Conclusions
It is evident that research findings in the last few years have
sharpened our resolution of the processes that are affected by
lithium treatment in the context of bipolar pathology. Results
from differentiated iPS cells have been the most perceptive—
revealing disorder-associated protein and electrophysiological
changes that are reversed by lithium and distinguish patient
response profiles. Such cells will be vital tools to help bridge
the biological gap between the known genetic factors control-
ling lithium response and quantifiable electrophysiology.With
current advances in microfluidic devices that model neural
networks and the emergence of organoid production, we
may soon be able to examine lithium’s effects at higher func-
tional levels: brain structural changes and the connectivity
changes that might underlie its mood stabilizing activities.
Genomic studies, however, are still on a cusp—mirroring the
state of complex disease gene identification some 5 years ago,
immediately before meta-analyses pushed case numbers into
the high thousands and unleashed a torrent of significant SNP
findings. Doubtless that will come, and in the meantime we
should be cautious not to over-interpret. Ultimately, the hope
is that the genomic Venn diagram of lithium response and
bipolar disorder risk will overlap in a restricted but insightful
manner and, in this way, give drug companies clear direction
for the development of equally potent but safer alternatives to
lithium.
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